IL6 and neoplasm: Given a dual role of IL-6 in immunosuppressive cytokine-mediated pro-tumor effects immunity and CD40-mediated anti-tumor immunity (Fig. 3), we next sought to test experimental therapy that combines CD40 agonist to maximize tumor immunity in anti-IL-6 treatment.